Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Mitoxantrone in Relapsed AML
NCT00268242Phase 2Terminated
- Sponsor
- Cleveland Clinic
- Start
- Jan 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in acute myeloid leukemia (AML), sponsored by Cleveland Clinic. Primary endpoints: Complete Response Rate at 4 weeks and Duration of the First Complete Response up to 5 years. Started Jan 2006; status: terminated.
02
Drugs
gemcitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00268242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268242.